Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 7 May 2018 |
| Orion Corporation: Managers' transactions - Eija Ronkainen | 3 May 2018 |
| Orion Corporation: Managers' transactions - Hilpi Rautelin | 3 May 2018 |
| Orion Corporation: Managers' transactions - Mikael Silvennoinen | 3 May 2018 |
| Orion Corporation: Managers' transactions - Heikki Westerlund | 3 May 2018 |